To determine whether CMKLR1 agonists might be relevant in ocular neovascular diseases, we used a mouse model of oxygen-induced retinopathy (OIR) that closely recapitulates the two phases of retinopathy of prematurity (ROP) [33]. This evidence concerns the gene CMKLR1 and retinopathy of prematurity.